A study investigating the therapeutic effect of vonoprazan on the patients with proton pump inhibitor resistant eosinophilic esophagitis

A study investigating the therapeutic effect of vonoprazan on the patients with proton pump inhibitor resistant eosinophilic esophagitis - A study investigating the therapeutic effect of vonoprazan on the patients with proton pump inhibitor resistant eosinophilic esophagitis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000021041

Enrollment

Registered

2016-02-15

Start date

2016-02-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Eosinophilic esophagitis

Interventions

administration of Vonoprazan (20mg/day for 2 months)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with EoE who are resistant to initial PPI therapy

Exclusion criteria

Exclusion criteria: 1)Patients with advanced malignant disease 2)Patients who are administrated the drug which affects their condition 3)Patients who are not eligible for participation judged by a resercher

Design outcomes

Primary

Measure	Time frame
improvement of esophageal eosinophilia after administration for 2 months	—

Secondary

Measure	Time frame
symptom improvement	—

Countries

Japan

Contacts

Public ContactNorihisa Ishimura

Shimane University Faculty of Medicine Second department of Internal Medicine

ishimura@med.shimane-u.ac.jp0853-20-2190

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026